Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 5/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | STS | P08842 | 9/20 | 0.62 |
| ▸ | CA1 | P00915 | 3/20 | 0.61 |
| ▸ | CA2 | P00918 | 3/20 | 0.61 |
| ▸ | CA9 | Q16790 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | ESR1 | P03372 | 2/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.61 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.61 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.61 |
| ▸ | CA4 | P22748 | 1/20 | 0.61 |
| ▸ | CA6 | P23280 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6691697 | 0.85 | HSD17B1 (0.74) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL10134113 | 0.85 | HSD17B1 (0.74) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL1027643 | 0.82 | HSD17B1 (0.83) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL14044784 | 0.81 | HSD17B1 (0.74) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL11672003 | 0.81 | HSD17B1 (0.74) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL8034790 | 0.81 | STS (0.72) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL11671118 | 0.81 | HSD17B1 (0.78) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL5527434 | 0.81 | HSD17B1 (0.78) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL6684274 | 0.81 | HSD17B1 (0.84) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL14416886 | 0.80 | HSD17B1 (0.76) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2111409-B1 | NOVEL CATIONIC 17 ALPHA- SUBSTITUTED-ESTRADIOL DERIVATIVES USEFUL AS ANTI-CANCER AGENT | COUNCIL SCIENT IND RES (IN) | 2012-06-27 | — | — | EP | disclosed |
| US-8012952-B2 | Cationic 17 α-substituted-estradiol derivatives useful as anti-cancer agent | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2011-09-06 | — | — | US | disclosed |
| EP-1023315-B1 | METHODS AND COMPOSITIONS FOR DESTRUCTION OF SELECTED PROTEINS | SLOAN KETTERING INST CANCER (US) | 2010-03-10 | — | — | EP | disclosed |
| EP-2111409-A1 | NOVEL CATIONIC 17 ALPHA- SUBSTITUTED-ESTRADIOL DERIVATIVES USEFUL AS ANTI-CANCER AGENT | Council of Scientific&Industrial Research (IN) | 2009-10-28 | — | — | EP | disclosed |
| US-20090062230-A1 | NOVEL CATIONIC 17 ALPHA-SUBSTITUTED-ESTRADIOL DERIVATIVES USEFUL AS ANTI-CANCER AGENT | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2009-03-05 | — | — | US | disclosed |
| WO-2008099414-A1 | NOVEL CATIONIC 17 α- SUBSTITUTED-ESTRADIOL DERIVATIVES USEFUL AS ANTI-CANCER AGENT | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2008-08-21 | — | — | WO | disclosed |
| EP-1023315-A4 | METHODS AND COMPOSITIONS FOR DESTRUCTION OF SELECTED PROTEINS | SLOAN KETTERING INSTITUTEFOR C (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6670348-B1 | Antitumor geldanamycins | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-12-30 | — | — | US | disclosed |
| EP-1023315-A1 | METHODS AND COMPOSITIONS FOR DESTRUCTION OF SELECTED PROTEINS | Sloan-Kettering Institute For Cancer Research (US) | 2000-08-02 | — | — | EP | disclosed |
| WO-1998051702-A1 | METHODS AND COMPOSITIONS FOR DESTRUCTION OF SELECTED PROTEINS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1998-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062230-A1 | NOVEL CATIONIC 17 ALPHA-SUBSTITUTED-ESTRADIOL DERIVATIVES USEFUL AS ANTI-CANCER AGENT | ESR2, ESR1, GPER1 | HSD17B1 26/4885LMNA 656/4885MAPT 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.